tiprankstipranks
Trending News
More News >
Surgical Science Sweden AB (SE:SUS)
:SUS
Sweden Market
Advertisement

Surgical Science Sweden AB (SUS) AI Stock Analysis

Compare
1 Followers

Top Page

SE:SUS

Surgical Science Sweden AB

(SUS)

Rating:57Neutral
Price Target:
kr104.00
▲(10.11% Upside)
Surgical Science Sweden AB's overall stock score is primarily influenced by its strong financial performance, which is offset by bearish technical indicators and a relatively high valuation. The lack of earnings call data and corporate events means these factors do not contribute to the score. The company's robust financial health supports its long-term growth potential, but current market sentiment and valuation present short-term challenges.

Surgical Science Sweden AB (SUS) vs. iShares MSCI Sweden ETF (EWD)

Surgical Science Sweden AB Business Overview & Revenue Model

Company DescriptionSurgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence-based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim ST develops to train surgical technologists and surgical assistants; and LapSim essence, a portable and ready-to-use VR simulator. The company also provides EndoSim system, an endoscopy simulator that delivers medical simulation training; TeamSim, a dynamic platform for inter-professional education development taking surgery simulation into the real world teamwork; Simball Box, which offers feedback on velocity with tutorial task videos showing a preferred approach; simbionix simulators; and robotic surgery simulators. Surgical Science AB was founded in 1999 and is headquartered in Gothenburg, Sweden.
How the Company Makes MoneySurgical Science Sweden AB generates revenue primarily through the sale of its VR simulation platforms to hospitals, medical universities, and training institutions worldwide. The company also earns income from software licenses, ongoing support, and maintenance services for its simulation systems. Additionally, Surgical Science may engage in strategic partnerships with medical device manufacturers and educational organizations to expand its market reach and product offerings. These partnerships can involve joint development projects or distribution agreements that further drive sales and adoption of their simulation technologies.

Surgical Science Sweden AB Financial Statement Overview

Summary
Surgical Science Sweden AB demonstrates a strong financial profile with consistent revenue growth and robust profitability margins. The company maintains a healthy balance sheet with low leverage and strong cash reserves. While there is some decline in net income and cash flow, the company remains well-positioned for sustainable growth in the medical healthcare information services industry.
Income Statement
75
Positive
Surgical Science Sweden AB has shown consistent growth in total revenue over the years, with the latest annual revenue reaching SEK 884 million. The company maintains a strong gross profit margin, indicating efficient cost management. However, the decline in net income from SEK 234 million in 2023 to SEK 132 million in 2024 has impacted the net profit margin. The EBIT and EBITDA margins remain healthy, reflecting the company's operational efficiency.
Balance Sheet
80
Positive
The balance sheet reveals a robust financial position, with a high equity ratio and low debt-to-equity ratio, indicating stable financial leverage. The shareholder's equity has significantly increased over the years, supporting the company's growth. The company has a strong cash position, with cash and short-term investments totaling SEK 968 million, enhancing its liquidity.
Cash Flow
70
Positive
Cash flow analysis shows positive operating cash flow, although it has decreased from the previous year. The free cash flow remains positive, supporting the company's ability to invest in future growth. Despite a drop in free cash flow from SEK 194 million in 2023 to SEK 90 million in 2024, the operating cash flow to net income ratio remains satisfactory, reflecting efficient cash management.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue943.23M884.09M882.85M802.54M366.78M104.80M
Gross Profit640.08M597.90M612.88M531.52M265.94M88.36M
EBITDA125.21M224.29M324.53M271.30M115.05M30.22M
Net Income92.45M131.65M233.97M187.97M86.25M15.61M
Balance Sheet
Total Assets4.71B5.48B4.70B4.65B3.98B472.27M
Cash, Cash Equivalents and Short-Term Investments610.22M968.15M634.37M433.73M316.68M87.16M
Total Debt1.64M292.35M40.02M14.68M12.07M2.32M
Total Liabilities406.24M651.03M357.46M413.11M393.06M45.22M
Stockholders Equity4.31B4.83B4.35B4.24B3.59B427.05M
Cash Flow
Free Cash Flow42.08M89.69M194.16M94.94M24.71M14.53M
Operating Cash Flow90.02M137.22M238.29M129.49M39.08M23.23M
Investing Cash Flow-132.86M-47.53M-44.13M-34.55M-2.73B-8.69M
Financing Cash Flow-1.12M227.65M15.85M17.09M2.92B4.21M

Surgical Science Sweden AB Technical Analysis

Technical Analysis Sentiment
Negative
Last Price94.45
Price Trends
50DMA
128.74
Negative
100DMA
135.81
Negative
200DMA
144.39
Negative
Market Momentum
MACD
-9.68
Negative
RSI
26.92
Positive
STOCH
4.36
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SUS, the sentiment is Negative. The current price of 94.45 is below the 20-day moving average (MA) of 99.11, below the 50-day MA of 128.74, and below the 200-day MA of 144.39, indicating a bearish trend. The MACD of -9.68 indicates Negative momentum. The RSI at 26.92 is Positive, neither overbought nor oversold. The STOCH value of 4.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SUS.

Surgical Science Sweden AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
kr4.82B52.13
12.52%-53.24%
51
Neutral
$7.95B-0.40-41.67%2.21%22.29%-1.85%
$111.28M-35.36%
$568.61M53.755.17%
€83.05M-5.83%
€166.19M7.05114.45%
€99.03M42.197.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SUS
Surgical Science Sweden AB
94.45
-24.35
-20.50%
SNZZF
Senzime AB
0.69
-0.11
-13.75%
XVIPF
Xvivo Perfusion AB
18.11
-28.77
-61.37%
DE:5JE
Bactiguard Holding AB
2.32
-3.18
-57.82%
DE:30S
Saniona AB
1.19
0.76
176.74%
DE:24C
C-Rad AB Class B
2.81
-0.69
-19.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 09, 2025